Hodnota metriky Předpokládaný růst EPS Q/Q společnosti Neuland Laboratories Limited je 66.02%
Očekávaný čtvrtletní růst EPS (Estimated quarterly EPS growth rate) meziročně je předpokládaným nárůstem EPS společnosti pro příští čtvrtletí ve srovnání s výsledkami z minulého čtvrtletí.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, antiemetic, central nervous system, fluoroquinolones, corticosteroids, antipsychotic, antibacterial and anti-parkinson, anti-ulcerants, and prostaglandins. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was founded in 1984 and is headquartered in Hyderabad, India.